Search results for "Drug Administration"

showing 10 items of 393 documents

The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with …

2012

Aims The objective was to assess the consistency of effect of switching to ezetimibe/simvastatin 10/20 mg versus doubling the baseline statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg across subgroups of subjects with (n = 617) and without (n = 191) metabolic syndrome (MetS). Methods This was a post hoc analysis of a randomized, double-blind, 6-week study of adults 18–79 years with cardiovascular disease and diabetes mellitus with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160 mg/dl. The percent change in LDL-C and other lipids was estimated within each subgroup separately. Safety and tolerability were assessed. Results In subjects with M…

Blood GlucoseMaleSimvastatinEndocrinology Diabetes and MetabolismAtorvastatinEzetimibe Simvastatin Drug CombinationPharmacologyEndocrinologyAtorvastatinMedicineRosuvastatin CalciumMetabolic SyndromeSulfonamidesAnticholesteremic AgentsFastingMiddle AgedDrug CombinationsTreatment OutcomeTolerabilityCardiovascular Diseaseslipids (amino acids peptides and proteins)Drug Therapy CombinationFemalemedicine.drugAdultmedicine.medical_specialtyStatinAdolescentmedicine.drug_classUrologyDrug Administration ScheduleEzetimibeDouble-Blind MethodDiabetes mellitusInternal MedicineHumansRosuvastatinPyrrolescardiovascular diseasesAgedApolipoproteins Bbusiness.industrynutritional and metabolic diseasesCholesterol LDLmedicine.diseaseFluorobenzenesDiabetes Mellitus Type 1PyrimidinesDiabetes Mellitus Type 2SimvastatinHeptanoic AcidsAzetidinesMetabolic syndromebusinessDiabetic AngiopathiesDiabetes, obesitymetabolism
researchProduct

Thrombocytopenia Associated With Levodopa Treatment

2003

Blood PlateletsMalemedicine.medical_specialtyLevodopaChemotherapyTime FactorsBenserazidePlatelet Countbusiness.industrymedicine.medical_treatmentDopamine AgentsThrombocytopeniaGastroenterologyDrug Administration ScheduleSurgeryAntiparkinson AgentsLevodopaCarbon-Carbon LyasesInternal medicineInternal MedicinemedicineHumansbusinessAgedmedicine.drugArchives of Internal Medicine
researchProduct

Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage.

2009

OBJECTIVE: Intracerebral hemorrhage (ICH) is a devastating clinical syndrome for which no truly efficacious therapy has yet been identified. In preclinical studies, erythropoietin (EPO) and its long-lasting analog, darbepoetin alfa, have been demonstrated to be neuroprotective in several models of neuronal insult. The objectives of this study were to analyze whether the systemic administration of recombinant human EPO (rHuEPO) and its long-lasting derivative darbepoetin alfa expedited functional recovery and brain damage in a rat model of ICH. METHODS: Experimental ICH was induced in rats by injecting autologous blood into the right striatum under stereotactic guidance. Subsequently, animal…

Brain InfarctionMaleDarbepoetin alfaBrain EdemaBrain damageNeuroprotectionDrug Administration ScheduleCentral nervous system diseaseRats Sprague-DawleyBlood Transfusion AutologousErythropoietin; Erythropoietin derivative; Intracerebral hemorrhage; Neuroprotectionhemic and lymphatic diseasesEdemamedicineAnimalsHumansDarbepoetin alfaErythropoietinCerebral HemorrhageIntracerebral hemorrhagebusiness.industryBasal Ganglia HemorrhageBrainmedicine.diseaseNeuroprotectionCorpus StriatumRecombinant ProteinsRatsErythropoietin derivativeDisease Models AnimalNeuroprotective AgentsTreatment OutcomeErythropoietinAnesthesiaErythropoietin Erythropoietin derivative Intracerebral hemorrhage NeuroprotectionSystemic administrationHematinicsSurgeryNeurology (clinical)medicine.symptomIntracerebral hemorrhagebusinessmedicine.drugNeurosurgery
researchProduct

Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: A non-inferiority, randomised, double-blind clinical tr…

2015

Summary Background Treatment guidelines for patients with moderate persistent asthma recommend regular therapy with a combination of an inhaled corticosteroid and a longacting β 2 agonist plus as-needed rapid-acting bronchodilators. We investigated whether symptom-driven budesonide and formoterol combination therapy administered as needed would be as effective as regular treatment with this combination plus as-needed symptom-driven terbutaline for patients with moderate asthma. Methods In this non-inferiority randomised clinical trial, we recruited adult patients (18–65 years of age) with stable moderate persistent asthma, according to 2006 Global Initiative for Asthma guidelines. Patients …

BudesonideMalePediatricsKaplan-Meier Estimatelaw.inventionRandomized controlled triallawMedicineOutpatient clinicBudesonide Formoterol Fumarate Drug CombinationAnti-Asthmatic AgentsTreatment Failureeducation.field_of_studyasthma; clinical trialMedicine (all)clinical trialMiddle AgedCombined Modality TherapyBronchodilator AgentsFemalemedicine.drugHumanAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentTerbutalinePopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPlaceboDrug Administration ScheduleNOYoung AdultDouble-Blind MethodAdministration InhalationTerbutalineinhaled corticosteroids LABA asthma clinical trialHumansAnti-Asthmatic AgenteducationBronchodilator AgentPulmonary and Respiratory Medicine; Medicine (all)AsthmaAgedPulmonary and Respiratory Medicine RCT asthmabusiness.industryComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKSmedicine.diseaseAsthmarespiratory tract diseasesFormoterolbusiness
researchProduct

Catumaxomab: a bispecific trifunctional antibody.

2009

The trifunctional bispecific monoclonal antibody catumaxomab has two binding specificities directed at epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells such as dendritic cells, macrophages and natural killer cells. The trifunctional approach thus leads to unrestricted but specific killing of epithelial tumor cells by major histocompatibility complex without the need for preactivation or external costimulation. The tumor-associated antigen EpCAM is strongly expressed in carcinomas of various origins including colon, rectum, ovarian, gastric, esophagus, lung, pancreas, breast and head and neck. Expressio…

CD3CatumaxomabAntineoplastic AgentsMajor histocompatibility complexchemistry.chemical_compoundAntigenAntigens NeoplasmNeoplasmsAntibodies BispecificMedicineAnimalsHumansPharmacology (medical)PharmacologybiologyBispecific monoclonal antibodybusiness.industryDrug Administration RoutesModels ImmunologicalEpithelial cell adhesion moleculeGeneral MedicineTrifunctional antibodychemistrybiology.proteinCancer researchAntibodyDrug Screening Assays Antitumorbusinessmedicine.drugDrugs of today (Barcelona, Spain : 1998)
researchProduct

Prevention of chemotherapy-induced anemia and thrombocytopenia by constant administration of stem cell factor.

2011

Abstract Purpose: Chemotherapy-induced apoptosis of immature hematopoietic cells is a major cause of anemia and thrombocytopenia in cancer patients. Although hematopoietic growth factors such as erythropoietin and colony-stimulating factors cannot prevent the occurrence of drug-induced myelosuppression, stem cell factor (SCF) has been previously shown to protect immature erythroid and megakaryocytic cells in vitro from drug-induced apoptosis. However, the effect of SCF in vivo as a single myeloprotective agent has never been elucidated. Experimental Design: The ability of SCF to prevent the occurrence of chemotherapy-induced anemia and thrombocytopenia was tested in a mouse model of cisplat…

Cancer ResearchAnemiamedicine.medical_treatmentSCF Bcl-2/Bcl-XL–positiveStem cell factorAntineoplastic AgentsBone Marrow CellsInbred C57BLDrug Administration ScheduleMiceSettore MED/04 - PATOLOGIA GENERALEmedicineAnimalsCisplatinErythroid Precursor CellsChemotherapyStem Cell Factorbusiness.industryAnemiamedicine.diseaseAnemia; Animals; Antineoplastic Agents; Bone Marrow Cells; Cisplatin; Drug Administration Schedule; Erythroid Precursor Cells; Female; Megakaryocytes; Mice; Mice Inbred C57BL; Stem Cell Factor; Thrombocytopenia; Oncology; Cancer ResearchThrombocytopeniaMice Inbred C57BLHaematopoiesisCytokinemedicine.anatomical_structureOncologyErythropoietinImmunologyCancer researchFemaleBone marrowCisplatinbusinessMegakaryocytesmedicine.drugClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

2011

Abstract Purpose: To facilitate development of innovative immunotherapy approaches, especially for treatment concepts exploiting the potential benefits of personalized therapy, there is a need to develop and validate tools to identify patients who can benefit from immunotherapy. Despite substantial effort, we do not yet know which parameters of antitumor immunity to measure and which assays are optimal for those measurements. Experimental Design: The iSBTc-SITC (International Society for Biological Therapy of Cancer-Society for Immunotherapy of Cancer), FDA (Food and Drug Administration), and NCI (National Cancer Institute) partnered to address these issues for immunotherapy of cancer. Here…

Cancer ResearchPathologymedicine.medical_specialtyHealth Planning Guidelinesmedicine.medical_treatmentConsensus Development Conferences as TopicStandardized testImmune monitoringt-cell immunity cytokine flow-cytometry cancer vaccine consortium colony-stimulating factor b elispot assay phase-ii trial dendritic cells clinical-trials hiv vaccine harmonization guidelinesMedical OncologyArticleFood and drug administrationNeoplasmsmedicineBiomarkers TumorHumansMedical physicsPersonalized therapySocieties MedicalAntitumor immunitybusiness.industryQuality assessmentUnited States Food and Drug AdministrationCancerInternational AgenciesImmunotherapymedicine.diseaseNational Cancer Institute (U.S.)United StatesOncologyPractice Guidelines as TopicImmunotherapybusiness
researchProduct

Cardiovascular Damage in Clinical Trials

2018

The Cardio-oncology field has grown considerably in the last two decades. The remarkable increase in the number of molecules used in oncology has brought with it a huge set of cardiovascular adverse events. For this reason, it is necessary to intervene on the early stages of drug development. This is what the Food and Drug Administration aims to do. This purpose can be achieved through a more careful analysis of the adverse event, development of guidelines, and identification of objective parameters that could guide the researcher in defining precisely the adverse event. It is also necessary to use additional methods not yet used in clinical trials that can allow an early detection of adver…

Cardiotoxicitymedicine.medical_specialtybusiness.industryfood and beveragesEarly detectionClinical trialFood and drug administrationDrug developmentmedicineCardio oncologyIntensive care medicineAdverse effectSet (psychology)business
researchProduct

Dose Responsive Effects of Subcutaneous Pentosan Polysulfate Injection in Mucopolysaccharidosis Type VI Rats and Comparison to Oral Treatment

2014

Background We previously demonstrated the benefits of daily, oral pentosan polysulfate (PPS) treatment in a rat model of mucopolysaccharidosis (MPS) type VI. Herein we compare these effects to once weekly, subcutaneous (s.c.) injection. The bioavailability of injected PPS is greater than oral, suggesting better delivery to difficult tissues such as bone and cartilage. Injected PPS also effectively treats osteoarthritis in animals, and has shown success in osteoarthritis patients. Methodology/principal findings One-month-old MPS VI rats were given once weekly s.c. injections of PPS (1, 2 and 4 mg/kg, human equivalent dose (HED)), or daily oral PPS (4 mg/kg HED) for 6 months. Serum inflammato…

Cartilage ArticularMaleMucopolysaccharidosisMucopolysaccharidosis type VIlcsh:MedicineAdministration OralOsteoarthritisOral administrationMedicine and Health SciencesFemurGrowth Platelcsh:Sciencehealth care economics and organizationsGlycosaminoglycansPentosan Sulfuric PolyesterMucopolysaccharidosis VIMultidisciplinaryMucopolysaccharidosis VIPentosan polysulfateBiomechanical Phenomena3. Good healthFemaleAnatomyResearch Articlemedicine.drugmedicine.medical_specialtyInflammatory DiseasesInjections SubcutaneousMovementeducationUrologyBiological AvailabilityResearch and Analysis MethodsDrug Administration ScheduleAutosomal Recessive DiseasesGeneticsmedicineAnimalsAnimal Models of DiseaseBoneAdverse effectMolecular BiologyClinical GeneticsDose-Response Relationship Drugbusiness.industrylcsh:RTherapeutic effectBiology and Life SciencesMucopolysaccharidosesmedicine.diseaseSpineRatsSurgeryAnimal Studieslcsh:QVeterinary ScienceTomography X-Ray ComputedbusinessPLoS ONE
researchProduct

A survey of mycotoxins in random street-vended snacks from Lagos, Nigeria, using QuEChERS-HPLC-MS/MS

2013

Abstract A survey in African snacks was carried out in order to evaluate the intake of 23 mycotoxins. The African snack samples were purchased from street vendors within Lagos metropolis (Nigeria) and evaluated for the presence of 23 mycotoxins using a modified QuEChERS procedure coupled with liquid chromatography-triple quadrupole linear ion trap mass spectrometer. The snacks included akara, baked coconut, coconut candy, donkwa, groundnut cake (kulikuli), lafun, milk curd (wara), fresh and dried tiger-nuts, and yam flour. Only three mycotoxins were detected in 23.8% of the studied snacks, and at concentrations ranging from 6 to 54 μg kg−1. The concentrations of aflatoxin B1 (AFB1) and AFB2…

CassavaAflatoxinCoconutMycotoxinsQuechersFood and drug administrationGroundnutchemistry.chemical_compoundHplc ms mschemistryFood scienceLC-MS/MSSnacksMycotoxinFood ScienceBiotechnologyMathematicsFood Control
researchProduct